转甲状腺素蛋白淀粉样变心肌病的现有与新兴治疗选择
本文综述转甲状腺素蛋白淀粉样变(ATTR)心肌病的治疗进展。现有治疗包括TTR稳定剂(tafamidis、acoramidis)和基因沉默疗法(patisiran、inotersen、vutrisiran)。新兴策略包括CRISPR-Cas9基因编辑(nexiguran ziclumeran)、单克隆抗体和泛淀粉样抗体,旨在清除已沉积的淀粉样纤维。
要点
- TTR稳定剂和基因沉默疗法已改变ATTR淀粉样变的治疗格局。
- 清除已沉积淀粉样纤维仍是重要未满足临床需求。
- 联合不同机制治疗是否带来额外预后获益尚待明确。
核心结论
- ATTR特异性疾病修饰疗法的成功已使ATTR淀粉样变从进行性致死性疾病转变为可治疗疾病。
研究设计与样本
- 本文为综述,未报告系统检索范围。
主要发现
- TTR稳定剂可防止TTR四聚体解离为单体和寡聚体,后者随后形成淀粉样纤维。
- 基因沉默疗法抑制肝脏合成TTR,即淀粉样前体蛋白。
- CRISPR-Cas9基因编辑技术nexiguran ziclumeran若成功,有望实现单剂治疗。
- 单克隆抗体(cormitug、ALXN220)和泛淀粉样抗体(AT-02)旨在靶向并清除已沉积于心肌的淀粉样纤维。
临床怎么用
- 临床实践中可使用TTR稳定剂(tafamidis、acoramidis)和基因沉默疗法(patisiran、inotersen、vutrisiran)。
局限性
- 这些药物的长期安全性尚不明确。
- 联合不同作用机制治疗是否具有额外预后获益尚不明确。
- 如何最佳监测治疗反应尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Transthyretin amyloidosis (ATTR) is a condition caused by TTR protein misfolding and amyloid deposition, particularly in the heart and nervous system, leading to organ dysfunction. Advances in therapeutic strategies have revolutionised the management of ATTR amyloidosis. Treatments available in clinical practice include TTR stabilisers (tafamidis and acoramidis), which prevent the dissociation of TTR tetramer into monomers and oligomers that subsequently form amyloid fibrils, and gene-silencing therapies (patisiran, inotersen and vutrisiran), which suppress the hepatic synthesis of TTR, which is the amyloid precursor protein. Novel treatment strategies that are at various stages of development include Clustered Regularly Interspaced Short Palindromic Repeats-Cas9 gene-editing technology (nexiguran ziclumeran), which, if successful, offers the prospect of a single-dose treatment, and monoclonal (cormitug and ALXN220) and pan-amyloid antibodies (AT-02) that seek to target and remove amyloid fibrils that have deposited in the myocardium. Amyloid removal remains a significant unmet clinical need, and hence, the ability to promote amyloid degradation and clearance through the use of antiamyloid therapies would represent a groundbreaking advancement in the treatment of ATTR amyloidosis. The success of ATTR-specific disease-modifying therapies has already altered the treatment landscape and changed the perception of ATTR amyloidosis from a progressive and fatal disease to one that is treatable through the availability of highly effective disease-modifying therapies. However, important questions remain, including the long-term safety of these drugs, whether combining therapies with different mechanisms of action has an additive prognostic benefit and how best to monitor the treatment response.
引用
- Vergaro G, Ferrari Chen YF, Ioannou A, et al. Current and emerging treatment options for transthyretin amyloid cardiomyopathy. Heart. 2026. PMID: 40425273. doi:10.1136/heartjnl-2024-325184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。